Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

CagriSema vs Eloralintide

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

CagriSema has stronger documented evidence (Phase 3) than Eloralintide (Phase 1/2) while both occupy the amylin class. When clinical-evidence tier is the deciding factor, CagriSema is the safer pick. Eloralintide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

CagriSema

Phase 3

Eloralintide

Phase 1/2

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

CagriSema Eloralintide
Class Amylin + GLP-1 combination Amylin receptor agonist (investigational)
Drug class Metabolic & Weight Metabolic & Weight
Mechanism Dual amylin + GLP-1 receptor agonism Long-acting amylin receptor agonist
Route SC injection SC injection
Half-life ~7 days Long-acting (weekly target)
Dosage (research) 2.4 mg / 2.4 mg SC weekly Trial doses undisclosed
Evidence tier Phase 3 Phase 1/2
Research depth 113 indexed (PubMed 49 · CT 32 · EPMC 32) 34 indexed (PubMed 8 · CT 22 · EPMC 4)
Availability Investigational Investigational
Reported risks GI effects; Phase 3 REDEFINE mixed results Early-stage trials

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick CagriSema or Eloralintide?

CagriSema has stronger documented evidence (Phase 3) than Eloralintide (Phase 1/2) while both occupy the amylin class. When clinical-evidence tier is the deciding factor, CagriSema is the safer pick. Eloralintide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between CagriSema and Eloralintide?

CagriSema is classed as Amylin + GLP-1 combination; Eloralintide is classed as Amylin receptor agonist (investigational). Reported mechanism: CagriSema, Dual amylin + GLP-1 receptor agonism; Eloralintide, Long-acting amylin receptor agonist. Reported half-life: CagriSema, ~7 days; Eloralintide, Long-acting (weekly target). Routes in published studies: CagriSema, SC injection; Eloralintide, SC injection.

Which has stronger evidence, CagriSema or Eloralintide?

CagriSema has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CagriSema is graded Phase 3, with 25 cited sources on its reference page and 113 indexed studies. Eloralintide is graded Phase 1/2, with 24 cited sources on its reference page and 34 indexed studies.

Which is more accessible, CagriSema or Eloralintide?

Neither CagriSema nor Eloralintide is an FDA-approved drug. Catalog status: CagriSema, Investigational; Eloralintide, Investigational.

Are CagriSema and Eloralintide ever combined?

CagriSema and Eloralintide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…